Teva says oral MS drug laquinimod may reduce brain tissue damage

TEL AVIV (Reuters) - Israel's Teva Pharmaceutical Industries and Sweden's Active Biotech said a Phase III clinical trial of laquinimod, an oral treatment for multiple sclerosis, demonstrated a beneficial impact on brain tissue damage.

via Reuters: Health News Read More Here..